Il meeting affronta i tumori dell’ipofisi dai meccanismi biologici e genetici agli strumenti diagnostici e alle opzioni di cura, includendo forme aggressive, alterazioni…
Riassunto a cura di Smart ECM
Info basate su dati pubblici Agenas. Smart ECM non è responsabile del corso e non ha accordi con il provider che lo organizza. Contattaci
I PitNET aggressivi sfidano le terapie standard
Il meeting aggiorna medici e professionisti coinvolti nella cura dei tumori ipofisari sulle novità biologiche, genetiche, diagnostiche e terapeutiche dei PitNET, con un approccio multidisciplinare alla gestione clinica.
Pituitary adenomas/PitNET represents a complex disease, with a wide spectrum of clinical manifestations, from small benign lesions to aggressive PitNET, according to the ability of secreting different hormones or pro-hormones orof invading the neighbouring anatomical structures and to treatment resistance. Macroadenomas can cause mass effect, consisting of visualfield defects, headache or hypopituitarism. People with hypopituitarism due to pituitary adenomas have an approximately 2-fold increase in all-cause mortality compared with the general population Some syndromes of pituitary hormone excess are also associated with excess all-cause mortality. Acromegaly was associated with a 2-fold increase in all-cause mortality rate in studies published before 2008, but not in more recently published studies or in the subgroups of patients who achieved biochemical control of the disease. Cushing disease has been associated with a 3-fold increase in all-cause mortality rate.
Aggressive PitNETs (APTs) are a small subset, around 10 % of all PitNETs, defined as tumours which are radiologically invasive with unusually rapid tumour growth or clinically relevant tumour growth despite optimal standard therapies Pituitary carcinomas (PCs) specifically denote APTs that have metastasised (craniospinal or systemic) and comprise up to 0.4 % of all PitNETs. Current guidelines for the management of APTs and PCs recommend treatment with surgery, radiotherapy and temozolomide; however by definition these tumours progress despite these therapies and treatment options beyond current recommendations are experimental. In this field, precision medicine management is a rapidly expanding area that enables delivery of molecular based personalised therapies, and this approach may improve outcomes for patients with PitNET. In the recent years, a wide number of research investigated the genetic, molecular and biological features of PitNETs, in order to predict the clinical behaviour of these neoplasia and to personalize the treatments.
The current event has the aim of updating participants on the latest biological, genetic and clinical acquisitions on PitNET and on their impact in the management of PitNET affected patients according to the new knowledge, that requires a close clinical collaboration between neuroendocrinologist, ophthalmologist, pathologists, neurosurgeons, radiotherapist and nuclear medicine physician. The meeting is part of the teaching activities of the Master Degree in Diagnosis and Treatment of pituitary disease - Faculty of Medicine, Università’ Cattolica del Sacro Cuore, Rome.
Tematiche:tumori ipofisariPitNETacromegaliamalattia di Cushingipersecrezione ormonaleradioterapia
Il programma dei due giorni
Gio26novembre
Programma
1st Day - Thursday, November 26th 2026
13:00Round table : Bone Session – Bone fragility in Pituitary Diseases
14:00Registrations
14:30IntroductionL. De Marinis, A. Bianchi
Welcome SpeechA.D. Ferone, L. Festa, A. Lenzi, G. Reimondo, A. Sgambato, A. Spada, G. Fioroni, R. Baldelli
Presidential lecture
15:00Update sulla consensus per la gestione multidisciplinare dell'acromegaliaA. Giustina
I session: New knowledges and acquisitions on PitNET
15:30Controversies in pathology reporting of PitNETM. Gessi, L. Poliani
16:10Lecture – Integration of molecular profiling in the diagnosis and prognostic stratification of PitNETsF. Roncaroli
16:30Radiomics in Pituitary Adenomas (PitNETs): From Imaging Biomarkers to Clinical TranslationM. Puig Domingo
16:50Digital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone-secreting pituitary tumorsF. Gatto
17:10Personalizing radiotherapy for PitNETs: indications, timing and modern techniquesA. Martino, G. Minniti
17:40Discussion on the topics covered
Presidential lecture
18:00Radiometabolic therapy in NET and PitNET: the Italian Experience 2026D. Ferone
18:30Conclusions
Ven27novembre
Programma
2nd Day -Friday November 27th , 2026
08:30Registration
Presidential lecture
09:00A concept of Pituitary Tumours Centers of Excellence - ptcoeF. Casanueva
II session: The emerging aspects of Pituitary diseases
09:30Genetic obesities, new treatments and real-world experienceP. Marzullo
09:50Lights and Shadows of rhGH therapy in the adultV. Gasco, D. Cuboni
10:10Long-acting growth hormone for pediatric GHD: state of the artM. Cappa
10:30Coffee Break
III session: Management of sellar and parasellar tumors
10:50The Genetic Landscape of GH Secreting PitNET: Current Evidences and future perspectivesG. L. Scaglione, G. Trivellin
11:20Patient Perceptions of pituitary incidentaloma diagnosis and follow-up: a Pituitary Society International patient SurveyN. Karavitaki
11:40Surgical management of sellar and parasellar tumors: technical adjuncts and modern outcomesF. Doglietto
12:00News in radiological techniques of aggressive Pituitary TumorsS. Gaudino
12:20The contribution of Nuclear Medicine: when and why?C. Caldarella
12:50Discussion on topics
13:10Light Lunch
IV session: Uptodate in Cushing’s disease
14:00Disease Burden in Cushing's Syndrome - mechanism and treatment strategiesA. Isidori
14:20Peripheral blockers and central acting drugs in the treatment of Cushing's diseaseC. Simeoli
14:40Combination therapy for Cushing’s diseaseR. Pivonello
15:00Real-life data on pasireotide in monotherapy or combined in active Cushing's diseaseM. Barbot
15:20Discussion on topics
Lecture
15:40Biological and clinical implications of the tumor microenvironment in non-functioning PitNETsM.D. Ilie
16:00Discussion on topics
16:20Closing remarks
Verifica di apprendimento Ecm
Dove si svolgerà
Il corso si tiene presso Hotel Donna Camilla Savelli, Via Garibaldi 27 - Roma, Roma.
Quanti crediti ECM ottengo e come arrivano su Co.Ge.A.P.S.?
«XIII Annual Meeting On Pituitary Tumors Uptodate On Pitnet From…» assegna 10 crediti ECM al superamento della verifica di apprendimento. I crediti vengono inviati dal provider "Dotcom Srl" al tuo account Co.Ge.A.P.S. dopo la conclusione del corso.
Si svolge online o in presenza?
In presenza: «XIII Annual Meeting On Pituitary Tumors Uptodate On Pitnet From…» si tiene a Via Garibaldi 27 - Roma, Roma.
Quanti partecipanti sono previsti per l'evento?
Per «XIII Annual Meeting On Pituitary Tumors Uptodate On Pitnet From…» sono previsti fino a 100 partecipanti.
Conviene rispetto a un corso FAD gratuito sullo stesso obiettivo?
Al momento non risultano alternative gratuite sullo stesso obiettivo: a costo zero «XIII Annual Meeting On Pituitary Tumors Uptodate On Pitnet From…» è la scelta più semplice.
Quanto pesa questo corso sull'obbligo del triennio 2026-2028?
Con 10 crediti, «XIII Annual Meeting On Pituitary Tumors Uptodate On Pitnet From…» copre il 6,7% dei 150 crediti richiesti nel triennio. Con l'esonero o la riduzione per chi ha completato il triennio precedente la quota sale.
A quale obiettivo formativo corrisponde questo evento?
«XIII Annual Meeting On Pituitary Tumors Uptodate On Pitnet From…» ha come obiettivo formativo "Documentazione clinica. Percorsi clinico-assistenziali diagnostici e riabilitativi, profili di assistenza - profili di cura", parte degli "Obiettivi formativi di processo".
Si tratta di un evento residenziale interattivo?
No, «XIII Annual Meeting On Pituitary Tumors Uptodate On Pitnet From…» non è un evento residenziale interattivo.
Quali metodi di insegnamento sono utilizzati nell'evento?
In «XIII Annual Meeting On Pituitary Tumors Uptodate On Pitnet From…» i metodi didattici previsti sono: lezioni magistrali, serie di relazioni su tema preordinato, tavole rotonde con dibattito tra esperti e confronto/dibattito tra pubblico ed esperto/i guidato da un conduttore ("l'esperto risponde").
L'evento si terrà in italiano?
Sì, «XIII Annual Meeting On Pituitary Tumors Uptodate On Pitnet From…» si terrà interamente in italiano.
Come funziona la verifica di presenza?
In «XIII Annual Meeting On Pituitary Tumors Uptodate On Pitnet From…» la presenza viene verificata tramite firma di presenza.
Come funziona la verifica di apprendimento?
In «XIII Annual Meeting On Pituitary Tumors Uptodate On Pitnet From…» la verifica dell'apprendimento avviene tramite questionario a risposta multipla.
Posso sommare più corsi di Dotcom Srl?
Sì: oltre a «XIII Annual Meeting On Pituitary Tumors Uptodate On Pitnet From…» puoi seguire tutti i corsi che vuoi di Dotcom Srl, non c'è un limite per provider.
